Though a benign condition, clinical and microscopic adenomyosis appears to act like cancer characterized by cell invasion, uncontrolled growth, neovascularization.1 In both in vivo and in vitro systems, LPA has been shown to participate in each of these processes, underscoring the involvement LPA and the potential therapeutic benefit of targeting LPA signaling. The gene discussed is LPA; the disease is adenomyosis.